Neutralizing and enhancing monoclonal antibodies in SARS-CoV-2 convalescent patients: lessons from early variant infection and impact on shaping emerging variants

References

• Dejnirattisai W, Zhou D, Supasa P, et al. Antibody evasion by the P.1 strain of SARS-CoV-2. Cell. 2021;184:2939–2954.e9. doi:10.1016/j.cell.2021.03.055
   PubMed Web of Science ®Google Scholar
• Wang P, Nair MS, Liu L, et al. Antibody resistance of SARS-CoV-2 variants B.1.351 and B.1.1.7. Nature. 2021;593:130–135. doi:10.1038/s41586-021-03398-2
   PubMed Web of Science ®Google Scholar
• Hoffmann M, Arora P, Groß R, et al. SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies. Cell. 2021;184:2384–2393.e12. doi:10.1016/j.cell.2021.03.036
   PubMed Web of Science ®Google Scholar
• Kaku Y, Kuwata T, Zahid HM, et al. Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19. Cell Rep. 2021;36:109385. doi:10.1016/j.celrep.2021.109385
   PubMed Web of Science ®Google Scholar
• Harvey WT, Carabelli AM, Jackson B, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol. 2021;19:409–424. doi:10.1038/s41579-021-00573-0
   PubMed Web of Science ®Google Scholar
• Zhou Y, Liu Z, Li S, et al. Enhancement versus neutralization by SARS-CoV-2 antibodies from a convalescent donor associates with distinct epitopes on the RBD. Cell Rep. 2021;34:108699. doi:10.1016/j.celrep.2021.108699
   PubMed Web of Science ®Google Scholar
• Li D, Edwards RJ, Manne K, et al. In vitro and in vivo functions of SARS-CoV-2 infection-enhancing and neutralizing antibodies. Cell. 2021;184:4203–4219.e32. doi:10.1016/j.cell.2021.06.021
   PubMed Web of Science ®Google Scholar
• Rojas M, Herrán M, Ramírez-Santana C, et al. Molecular mimicry and autoimmunity in the time of COVID-19. J Autoimmun. 2023;139:103070. doi:10.1016/j.jaut.2023.103070
   PubMed Web of Science ®Google Scholar
• Knight JS, Caricchio R, Casanova J-L, et al. The intersection of COVID-19 and autoimmunity. J Clin Invest. 2021;131:e154886. doi:10.1172/JCI154886
   PubMed Web of Science ®Google Scholar
• Kaplonek P, Fischinger S, Cizmeci D, et al. mRNA-1273 vaccine-induced antibodies maintain Fc effector functions across SARS-CoV-2 variants of concern. Immunity. 2022;55:355–365.e4. doi:10.1016/j.immuni.2022.01.001
   PubMed Web of Science ®Google Scholar
• Richardson SI, Manamela NP, Motsoeneng BM, et al. SARS-CoV-2 Beta and Delta variants trigger Fc effector function with increased cross-reactivity. Cell Rep Med. 2022;3:100510. doi:10.1016/j.xcrm.2022.100510
   PubMedGoogle Scholar
• Wang Z, Deng T, Zhang Y, et al. ACE2 can act as the secondary receptor in the FcγR-dependent ADE of SARS-CoV-2 infection. iScience. 2022;25:103720.
   PubMed Web of Science ®Google Scholar
• Okuya K, Hattori T, Saito T, et al. Multiple routes of antibody-dependent enhancement of SARS-CoV-2 infection. Microbiol Spectr. 2022;10:e0155321. doi:10.1128/spectrum.01553-21
   PubMed Web of Science ®Google Scholar
• Peddireddy SP, Rahman SA, Cillo AR, et al. Antibodies targeting conserved non-canonical antigens and endemic coronaviruses associate with favorable outcomes in severe COVID-19. Cell Rep. 2022;39:111020. doi:10.1016/j.celrep.2022.111020
   PubMed Web of Science ®Google Scholar
• Coutant F, Pin J-J, Morfin-Sherpa F, et al. Impact of host immune status on discordant anti-SARS-CoV-2 circulating B cell frequencies and antibody levels. Int J Mol Sci. 2021;22:11095. doi:10.3390/ijms222011095
   PubMed Web of Science ®Google Scholar
• Touret F, Gilles M, Barral K, et al. In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication. Sci Rep. 2020;10:13093. doi:10.1038/s41598-020-70143-6
   PubMed Web of Science ®Google Scholar
• Coutant F, Bachet R, Pin J-J, et al. Monoclonal antibodies from B cells of patients with anti-MDA5 antibody-positive dermatomyositis directly stimulate interferon gamma production. J Autoimmun. 2022;130:102831. doi:10.1016/j.jaut.2022.102831
   PubMed Web of Science ®Google Scholar
• Hernández S, Feracci M, Jesus D, et al. Identification of potent inhibitors of arenavirus and SARS-CoV-2 exoribonucleases by fluorescence polarization assay. Antiviral Res. 2022;204:105364. doi:10.1016/j.antiviral.2022.105364
   PubMed Web of Science ®Google Scholar
• Bahnan W, Wrighton S, Sundwall M, et al. Spike-Dependent opsonization indicates both dose-dependent inhibition of phagocytosis and that Non-neutralizing antibodies Can confer protection to SARS-CoV-2. Front Immunol. 2021;12:808932. doi:10.3389/fimmu.2021.808932
   PubMed Web of Science ®Google Scholar
• Zohar T, Loos C, Fischinger S, et al. Compromised humoral functional evolution tracks with SARS-CoV-2 mortality. Cell. 2020;183:1508–1519.e12. doi:10.1016/j.cell.2020.10.052
   PubMed Web of Science ®Google Scholar
• Zhang A, Stacey HD, Agostino D, et al. Beyond neutralization: Fc-dependent antibody effector functions in SARS-CoV-2 infection. Nat Rev Immunol. 2022: 1–16.
   PubMed Web of Science ®Google Scholar
• Zanella I, Degli Antoni M, Marchese V, et al. Non-neutralizing antibodies: deleterious or propitious during SARS-CoV-2 infection? Int Immunopharmacol. 2022;110:108943. doi:10.1016/j.intimp.2022.108943
   PubMed Web of Science ®Google Scholar
• Wen J, Cheng Y, Ling R, et al. Antibody-dependent enhancement of coronavirus. Int J Infect Dis. 2020;100:483–489. doi:10.1016/j.ijid.2020.09.015
   PubMed Web of Science ®Google Scholar
• Mu S, Song S, Hao Y, et al. Neutralizing antibodies from the rare convalescent donors elicited antibody-dependent enhancement of SARS-CoV-2 variants infection. Front Med (Lausanne). 2022;9:952697. doi:10.3389/fmed.2022.952697
   PubMed Web of Science ®Google Scholar
• Shimizu J, Sasaki T, Koketsu R, et al. Reevaluation of antibody-dependent enhancement of infection in anti-SARS-CoV-2 therapeutic antibodies and mRNA-vaccine antisera using FcR- and ACE2-positive cells. Sci Rep. 2022;12:15612. doi:10.1038/s41598-022-19993-w
   PubMed Web of Science ®Google Scholar
• Arvin AM, Fink K, Schmid MA, et al. A perspective on potential antibody-dependent enhancement of SARS-CoV-2. Nature. 2020;584:353–363. doi:10.1038/s41586-020-2538-8
   PubMed Web of Science ®Google Scholar
• Ayala-Nunez NV, Hoornweg TE, van de Pol DPI, et al. How antibodies alter the cell entry pathway of dengue virus particles in macrophages. Sci Rep. 2016;6:28768. doi:10.1038/srep28768
   PubMed Web of Science ®Google Scholar
• Haslwanter D, Blaas D, Heinz FX, et al. A novel mechanism of antibody-mediated enhancement of flavivirus infection. PLoS Pathog. 2017;13:e1006643. doi:10.1371/journal.ppat.1006643
   PubMed Web of Science ®Google Scholar
• Oliphant T, Nybakken GE, Engle M, et al. Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein. J Virol. 2006;80:12149–12159. doi:10.1128/JVI.01732-06
   PubMed Web of Science ®Google Scholar
• Flynn DC, Olmsted RA, Mackenzie JM, et al. Antibody-mediated activation of Sindbis virus. Virology. 1988;166:82–90. doi:10.1016/0042-6822(88)90149-3
   PubMed Web of Science ®Google Scholar
• Liu Y, Soh WT, Kishikawa J-I, et al. An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies. Cell. 2021;184:3452–3466.e18. doi:10.1016/j.cell.2021.05.032
   PubMed Web of Science ®Google Scholar
• Liu Y, Arase H. Neutralizing and enhancing antibodies against SARS-CoV-2. Inflamm Regen. 2022;42:58. doi:10.1186/s41232-022-00233-7
   PubMed Web of Science ®Google Scholar
• Simon-Loriere E, Schwartz O. Towards SARS-CoV-2 serotypes? Nat Rev Microbiol. 2022;20:187–188. doi:10.1038/s41579-022-00708-x
   PubMed Web of Science ®Google Scholar